NanoViricides, Inc., a publicly traded company (NYSE:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Rare Pediatric Disease Drug" Designation (RPDD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD). This RPDD application is expected to be joined together with the Orphan Drug Designation application for NV-387 as a Treatment for Measles that the Company has filed in February, 2026.

NanoViricides will be eligible for a Priority Review Voucher (PRV) upon approval of the drug if NV-387 is designated as a Rare Pediatric Disease Drug. A PRV carries immediate economic value. It is a tradable instrument, and recently has generally fetched around $160 million upon sale of the PRV to another company [1]. A PRV carries the benefit of accelerated approval of the drug for which it is used by the purchaser, which brings this value to the PRV.